TiGenix bags €12m from Grifols unit to fund PhIII stem cell trial
This article was originally published in Clinica
Executive Summary
Belgian cell therapy company TiGenix has raised €12m in a private placement of 34 million shares with Gri-Cel, a subsidiary of Spanish pharma Grifols.